News & Updates
Filter by Specialty:
Aumolertinib a win in EGFR T790M-positive advanced NSCLC
The novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) aumolertinib appears to be effective in the treatment of patients with EGFR T790M-positive advanced nonsmall cell lung carcinoma (NSCLC) following progression on first- and second-generation EGFR TKI therapy, according to data from the phase II APOLLO Registrational Trial.
Aumolertinib a win in EGFR T790M-positive advanced NSCLC
23 Dec 2021
New algorithm predicts HCC risk in compensated advanced chronic liver disease
A novel algorithm using post-treatment age, albumin, and liver stiffness measurement (LSM), among other parameters, can accurately stratify patients with compensated advanced chronic liver disease (cACLD) according to their de novo hepatocellular carcinoma (HCC) risk, a new study shows.
New algorithm predicts HCC risk in compensated advanced chronic liver disease
19 Dec 2021
Remote management during chemotherapy fails to reduce ED visits, hospitalization
A remote, proactive, and telephone-based management of toxicities in outpatients during adjuvant or neoadjuvant chemotherapy for early-stage breast cancer does not lead to fewer visits to the emergency department (ED) or hospital admissions, a study has shown.
Remote management during chemotherapy fails to reduce ED visits, hospitalization
17 Dec 2021
Adjuvant palbociclib + ET does not improve outcomes vs ET alone in early breast cancer
Adjuvant palbociclib in combination with endocrine therapy (ET) does not improve invasive disease-free survival (iDFS) or secondary endpoints vs ET alone in patients with hormone receptor–positive, HER2-negative early breast cancer, final results of the phase III PALLAS trial have shown.
